Rapport Therapeutics Inc
NASDAQ:RAPP

Watchlist Manager
Rapport Therapeutics Inc Logo
Rapport Therapeutics Inc
NASDAQ:RAPP
Watchlist
Price: 11.8 USD 4.33% Market Closed
Market Cap: 430.7m USD

Relative Value

There is not enough data to reliably calculate the relative value of RAPP.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

RAPP Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.5
vs History
vs Industry
Median 3Y
-8.2
Median 5Y
-8.2
Industry
21.2
Forward
-3.5
vs History
vs Industry
Median 3Y
-10.2
Median 5Y
-10.2
Industry
16.3
vs History
vs Industry
Median 3Y
-9.8
Median 5Y
-9.8
Industry
23.8
vs History
60
vs Industry
Median 3Y
2.1
Median 5Y
2.1
Industry
2.1
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
2.6
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.2
vs History
vs Industry
Median 3Y
-4.5
Median 5Y
-4.5
Industry
12.5
Forward
-3.1
vs History
vs Industry
Median 3Y
-4.5
Median 5Y
-4.5
Industry
15.9
Forward
-3.1
vs History
vs Industry
Median 3Y
-6.3
Median 5Y
-6.3
Industry
14.6
vs History
vs Industry
Median 3Y
-6.1
Median 5Y
-6.1
Industry
17.2
vs History
66
vs Industry
Median 3Y
42
Median 5Y
42
Industry
1.8

Multiples Across Competitors

RAPP Competitors Multiples
Rapport Therapeutics Inc Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Rapport Therapeutics Inc
NASDAQ:RAPP
424.8m USD 0 -5.3 -4.6 -4.5
US
Eli Lilly and Co
NYSE:LLY
738.5B USD 15.1 66.5 35.7 39
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
374.2B USD 4.2 17.2 12.5 16.5
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.5 18.7 13 14.9
CH
Roche Holding AG
SIX:ROG
206.9B CHF 3.4 25 9.4 11
CH
Novartis AG
SIX:NOVN
193.3B CHF 4.6 19 11.2 14.9
UK
AstraZeneca PLC
LSE:AZN
161.1B GBP 4 28.3 130 196
US
Merck & Co Inc
NYSE:MRK
207.3B USD 3.2 11.9 8.8 10.7
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
143.9B USD 2.3 18.3 7.8 10.9
P/E Multiple
Earnings Growth PEG
US
Rapport Therapeutics Inc
NASDAQ:RAPP
Average P/E: 25.6
Negative Multiple: -5.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
66.5
49%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.2
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
18.7
18%
1
CH
Roche Holding AG
SIX:ROG
25
32%
0.8
CH
Novartis AG
SIX:NOVN
19
17%
1.1
UK
AstraZeneca PLC
LSE:AZN
28.3
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.9
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
18.3
30%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Rapport Therapeutics Inc
NASDAQ:RAPP
Average EV/EBITDA: 433.6
Negative Multiple: -4.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35.7
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.5
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
13
13%
1
CH
Roche Holding AG
SIX:ROG
9.4
5%
1.9
CH
Novartis AG
SIX:NOVN
11.2
5%
2.2
UK
AstraZeneca PLC
LSE:AZN
130
10%
13
US
Merck & Co Inc
NYSE:MRK
8.8
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.8
2%
3.9
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Rapport Therapeutics Inc
NASDAQ:RAPP
Average EV/EBIT: 1 867.2
Negative Multiple: -4.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.5
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
14.9
14%
1.1
CH
Roche Holding AG
SIX:ROG
11
6%
1.8
CH
Novartis AG
SIX:NOVN
14.9
10%
1.5
UK
AstraZeneca PLC
LSE:AZN
196
23%
8.5
US
Merck & Co Inc
NYSE:MRK
10.7
11%
1
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.9
10%
1.1